

# CITATION REPORT

List of articles citing

## Concepts and Challenges of Biosimilars in Breast Cancer: The Emergence of Trastuzumab Biosimilars

DOI: 10.3390/pharmaceutics10040168  
Pharmaceutics, 2018, 10, .

**Source:** <https://exaly.com/paper-pdf/70642695/citation-report.pdf>

**Version:** 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| #  | Paper  | IF   | Citations |
|----|--|------|-----------|
| 10 | Current status of nanomedicine in the chemotherapy of breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2019</b> , 84, 689-706   | 3.5  | 30        |
| 9  | Access to high-cost drugs for advanced breast cancer in Latin America, particularly trastuzumab. <i>Ecancermedicalscience</i> , <b>2019</b> , 13, 898  | 2.7  | 19        |
| 8  | Antibody therapeutics and immunoregulation in cancer and autoimmune disease. <i>Seminars in Cancer Biology</i> , <b>2020</b> , 64, 1-12  | 12.7 | 40        |
| 7  | Development of Innovative Formulations for Breast Cancer Chemotherapy. <i>Cancers</i> , <b>2020</b> , 12,  | 6.6  |           |
| 6  | A randomized phase I clinical trial comparing the pharmacokinetic, safety, and immunogenicity of potential biosimilar recombinant human HER2 monoclonal antibody for injection and trastuzumab in healthy Chinese adults. <i>Expert Opinion on Investigational Drugs</i> , <b>2020</b> , 29, 755-762 | 5.9  | 4         |
| 5  | Assessment of Structural and Functional Comparability of Biosimilar Products: Trastuzumab as a Case Study. <i>BioDrugs</i> , <b>2020</b> , 34, 209-223   | 7.9  | 13        |
| 4  | Biyobenzer Tabl. <i>Beykent Üniversitesi Fen Ve Mühendislik Bilimleri Dergisi</i> ,  |      |           |
| 3  | Biosimilars accessible in the market for the treatment of cancer. <i>Journal of Controlled Release</i> , <b>2021</b> , 336, 112-129  | 11.7 | 20        |
| 2  | Current and future roles of biosimilars in oncology practice. <i>Oncology Letters</i> , <b>2020</b> , 19, 45-51  | 2.6  | 8         |
| 1  | Establishing Analytical and Functional Comparability for Biosimilars. <b>2022</b> , 258-261  |      | 0         |